Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2009 Dec;18(4):279-86.
doi: 10.4104/pcrj.2009.00024.

Asthma control in primary care in Sweden: a comparison between 2001 and 2005

Affiliations
Comparative Study

Asthma control in primary care in Sweden: a comparison between 2001 and 2005

Björn Ställberg et al. Prim Care Respir J. 2009 Dec.

Abstract

Aim: To compare the degree of asthma control in 2001 and 2005 in a primary care setting in Sweden.

Method: Two similar questionnaire surveys were performed in 2001 and 2005 with 1,012 and 224 asthma patients aged 18-45 randomly selected from 42 and 56 primary health care centres, respectively. A classification of asthma control similar to the GINA guidelines was made using information obtained from the questionnaire.

Results: In 2001, 36.6% had achieved asthma control, 23.8% were partly controlled and 39.6% uncontrolled. In 2005, the corresponding figures were 40.2%, 26.8% and 33.0%, respectively, with no difference between the two surveys (p=0.114). Uncontrolled asthma was more common in women (p<0.001 in the first and p<0.05 in the second survey) and smokers (p<0.01 in the first and p<0.01 in the second survey). The use of combination corticosteroid/long-acting bronchodilator inhalers had increased - 34.2% and 48.2%, respectively (p<0.001) - and many patients used their inhaled corticosteroids periodically.

Conclusion: In spite of treatment guidelines many patients in Swedish primary care still have insufficient asthma control.

PubMed Disclaimer

Conflict of interest statement

Bjorn Stallberg has been paid for lectures and for consulting from AstraZeneca,

Publication types